Journals in Pharmacology

1-10 of 72 results in All results

Biochemical Pharmacology

ISSN: 0006-2952
5 Year impact factor: 5.8
Impact factor: 5.8

Biochemical Pharmacology publishes original research findings and review articles related to the elucidation of cellular and tissue function(s) at the biochemical and molecular levels, the modification of cellular phenotype(s) by genetic, transcriptional/translational or drug/compound-induced modifications, as well as the pharmacodynamics and pharmacokinetics of xenobiotics and drugs, the latter including both small molecules and biologics. The journal's target audience includes scientists engaged in the identification and study of the mechanisms of action of xenobiotics, biologics and drugs and in the drug discovery and development process. All areas of cellular biology and cellular, tissue/organ and whole animal pharmacology fall within the scope of the journal. Drug classes covered include anti-infectives, anti-inflammatory agents, chemotherapeutics, cardiovascular, endocrinological, immunological, metabolic, neurological and psychiatric drugs, as well as research on drug metabolism and kinetics. While medicinal chemistry is a topic of complementary interest, manuscripts in this area must contain sufficient biological data to characterize pharmacologically the compounds reported. Submissions describing work focused predominately on chemical synthesis and molecular modeling will not be considered for review. While particular emphasis is placed on reporting the results of molecular and biochemical studies, research involving the use of tissue and animal models of human pathophysiology and toxicology is of interest to the extent that it helps define drug mechanisms of action, safety and efficacy. Reports describing experiments conducted with natural product mixtures, plant or animal extracts will not be considered for publication unless the structures and concentrations of all component substances are known, and the agents can be easily obtained by others wishing to replicate the study. The chemical structure of all novel compounds tested must be included in the submitted manuscript or be readily accessible in the published literature. References to structures in the patent literature must unambiguously identify a single molecular structure. All compounds, reagents, instrumentation and equipment employed in a study must be available from identified commercial suppliers, bio/pharmaceutical companies or from individuals holding legal rights to their use. Submissions will not be considered for publication if the chemical structures of tested compounds are not revealed, generally known, or accessible in the literature. Original research submissions must contain: A rationale for the selection of the compound/drug for study as well as for the concentrations/doses employed. Quantities used for concentration- and dose-response experiments should vary logarithmically, e.g., 1, 3, 10, 30 mg/kg, 0.1, 1.0, 10, 100 nanomolar, etc. Justification must be provided for studying only a single concentration or dose of a compound, especially as it relates to reference standards and antagonists/modulators of receptors, enzymes and signaling pathways. Justification must also be provided for the selection of the statistical tests employed as they relate to the experimental design. It is expected that all findings have been subjected to rigorous quantitative analyses, with the calculation and reporting of IC50, Ki, EC50, etc., values. These must be derived from a minimum of three (3) separate and distinct experiments, with the replicates within any single experiment being averaged to obtain a single value for that experimental series. Manuscripts that fail to meet these criteria will be subject to rejection without peer-review. US National Institutes of Health (NIH) voluntary posting ("Public Access") policy Biochemical Pharmacology and Elsevier facilitate the author's response to the NIH Public Access Policy. Please bookmark this URL: https://www.elsevier.com/locate/biochempharm Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services . Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center

Contraception

ISSN: 0010-7824
5 Year impact factor: 2.9
Impact factor: 2.9

An international reproductive health journalThe Official Journal of the Society of Family Planning Contraception has an open access companion journal Contraception: X which has the same aims and scope, editorial board and peer-review process. To submit to Contraception: X visit https://www.editorialmanager.com/conx/default.aspx The journal Contraception wishes to advance reproductive health through the rapid publication of the best and most interesting new scholarship regarding contraception and related fields such as abortion. The journal welcomes manuscripts from investigators working in the laboratory, clinical and social sciences, as well as public health and health professions education.Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center

Current Therapeutic Research

ISSN: 0011-393X
5 Year impact factor: 2
Impact factor: 1.9

Current Therapeutic Research (CTR) is a multidisciplinary, peer-reviewed Open Access journal focusing on the discovery, development, and use of therapeutics and interventions across all therapeutic areas and all aspects of therapy. It is read by a large international audience of scientists and healthcare professionals in various research, academic, and clinical practice settings. Articles published in CTR are indexed by all major biomedical abstracting databases (e.g., PubMed/Medline, Clarivate, Scopus). CTR aims to publish high-quality, rigorous, and ethically sound original research, be it positive, confirmatory, or negative data, with the goal of improving healthcare. The journal welcomes in-depth review articles, meta-analyses, commentaries, brief reports, case reports, research letters, and letters to the editor. CTR promotes collaborative and interdisciplinary work with objectivity, criticism, creativity, innovation, and respect for cultural and professional diversity. By doing so, the journal provides a communication space for all therapists, regardless of their discipline or specialty. CTR areas of interest: Experimental medicine and therapeutics, translational medicine, clinical use of medicines and safe medication prescribing. Topics related to new or existing drug pharmacology, such as pharmacotherapy, pharmacovigilance, pharmacoeconomics, pharmacoepidemiology, personalized medicine and ethnopharmacology. Pharmaceutical topics including clinical trials, medicinal chemistry, drug disposition and effects, pharmaceutical medicine, pharmacodynamics, pharmacokinetics and toxicology. Pharmacometrics: PK/PD modeling, PBPK modeling, clinical trial modeling and simulation. Complementary medicine and therapies topics, including natural or herbal medicines that complement or replace conventional therapies - biological mechanisms of action, efficacy, safety, costs, patterns of use and implementation. Studies relating to stem-cell and nutritional therapy, diagnostics and diagnosis, public health, quality of life, patient care, management, and education are also encouraged. Interventions focused on all aspects of clinical therapy, including non-pharmacological ones. Emphasis will be placed on studies of specific topics such as pediatric clinical trials and pediatric and maternal-fetal pharmacology and toxicology. Research may involve preclinical and clinical studies and utilize both in vitro and in vivo approaches. Please note that the journal does not publish research on traditional medicines (e.g., traditional Chinese medicine, Kampo medicine, a Japanese traditional medicine) or studies involving crude natural products. Finally, CTR promotes inclusion and diversity by considering submissions from all over the world, whether they relate to an international or a country-specific audience (e.g., a specific patient population). Submit your manuscript at https://www.editorialmanager.com/curtherres.

European Journal of Pharmacology

ISSN: 0014-2999
5 Year impact factor: 4.6
Impact factor: 5

The European Journal of Pharmacology publishes research papers covering all aspects of experimental pharmacology with focus on the mechanism of action of structurally identified compounds affecting biological systems. The scope includes: Behavioural pharmacology, Neuropharmacology and psychopharmacology, Cardiovascular pharmacology, Pulmonary, gastrointestinal and urogenital pharmacology, Endocrine pharmacology, Immunopharmacology and inflammation, Molecular and cellular pharmacology, Regenerative pharmacology, Biologicals and biotherapeutics, Translational pharmacology and Nutriceutical pharmacology. The journal publishes full-length papers and reviews. Ethnopharmacological studies with plant extracts or mixtures are not in scope of this journal. The table of contents for this journal is now available pre-publication, via e-mail, as part of the free ContentsDirect service from Elsevier. Please send an e-mail message to [email protected] for further information about this service. Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services . Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center

Life Sciences

ISSN: 0024-3205
5 Year impact factor: 5.8
Impact factor: 6.1

Life Sciences is an international journal publishing articles that emphasize the molecular, cellular, and functional basis of therapy. The journal emphasizes the understanding of mechanism that is relevant to all aspects of human disease and translation to patients. All articles are rigorously reviewed. The Journal favors publication of full-length papers where modern scientific technologies are used to explain molecular, cellular and physiological mechanisms. Articles that merely report observations are rarely accepted. Recommendations from the Declaration of Helsinki or NIH guidelines for care and use of laboratory animals must be adhered to. Articles should be written at a level accessible to readers who are non-specialists in the topic of the article themselves, but who are interested in the research. The Journal welcomes reviews on topics of wide interest to investigators in the life sciences. We particularly encourage submission of brief, focused reviews containing high-quality artwork and require the use of mechanistic summary diagrams. Manuscripts should present novel preclinical findings addressing questions of biological significance to human disease. Studies that fail to do so may be rejected without review. Quantitative conclusions must be based on truly quantitative methods. Life Sciences does not publish work on the actions of biological extracts of unknown chemical composition. Compounds studied must be of known chemical structure and concentration. The study must be reproducible; materials used must be available to other researchers so they can repeat the experiment. Clinical studies may be considered if they expand understanding of mechanism, but the journal does not encourage clinical trial reports. Four common reasons for rejection include: out of scope (the manuscript does not conform to the goal of identification of mechanisms related to therapy for human disease); too preliminary (manuscript is based on a limited amount of experimental data diminishing significance); lack of novelty (manuscript is well done but does not address a significant question); unidentified structure (actions of biological extracts of unknown chemical composition).

Neuropharmacology

ISSN: 0028-3908
5 Year impact factor: 4.8
Impact factor: 4.7

Neuropharmacology publishes high quality, original research within the discipline of neuroscience. The emphasis of Neuropharmacology is on the study and understanding of the actions of known exogenous and endogenous chemical agents on neurobiological processes in the mammalian nervous system. Work with non-mammalian and invertebrate species may be considered in exceptional circumstances. The journal does not usually accept clinical research, although neuropharmacological studies in humans may be considered on the condition that they provide novel insight into either the actions of drugs and/or neurobiological mechanisms. The journal only considers submissions in which the chemical structures and compositions of experimental agents are readily available in the literature or disclosed by the authors in the submitted manuscript. Similarly, manuscripts describing the use of natural products will only be considered if the active ingredient is known and disclosed. The journal publishes Special Issues in which leading experts are invited to serve as Guest Editors to compile a collection of reviews, and occasionally original articles, around a particular topical theme in neuroscience research. The list of recent Special Issues can be found here. Suggestions for Special Issues can be made directly to the Editor-in-Chief. Neuropharmacology also publishes topical narrative reviews on subjects within its remit. These reviews are commissioned by the Editorial Team or arise after correspondence with potential authors. Unsolicited reviews will be considered, but authors are encouraged to contact the Editor-in-Chief of their intention to submit a review. Potential review authors should clearly indicate their expertise in the area, and how the review differs from, and adds to, recent published reviews on related topics. On the basis of the case made by authors, potential overlap with planned Neuropharmacology content, and discussions with the Editorial Team, the Editor-in-Chief will provide authors with a prompt decision regarding the proposed review. Systematic reviews, meta- or bibliographic analyses will not be considered unless they are a necessary part of a Special Issue and conducted by experts in the field, and even then only under exceptional circumstances and at the discretion of the Editor-in-Chief.

Therapies

ISSN: 0040-5957
5 Year impact factor: 2.1
Impact factor: 2.6

Official publication of the Société Française de Pharmacologie et de Thérapeutique (SFPT) – Organe officiel de la Société Française de Pharmacologie et de Thérapeutique (SFPT) Therapies is a peer-reviewed journal devoted to Clinical Pharmacology, Therapeutics, Pharmacokinetics, Pharmacovigilance, Addictovigilance, Social Pharmacology, Pharmacoepidemiology, Pharmacoeconomics and Evidence-Based-Medicine. Thérapie publishes in French or in English original articles, general reviews, letters to the editor reporting original findings, correspondence relating to articles or letters published in the Journal, short articles, editorials on up-to-date topics, Pharmacovigilance or Addictovigilance reports that follow the French "guidelines" concerning good practice in pharmacovigilance publications. The journal also publishes thematic issues on topical subject. The journal is indexed in the main international data bases and notably in: Biosis Previews/Biological Abstracts, Embase/Excerpta Medica, Medline/Index Medicus, Science Citation Index. Thérapies est un journal bimensuel consacré à des sujets de pharmacologie clinique, de thérapeutique, de pharmacocinétique, de pharmacovigilance, d'addictovigilance, de pharmacologie sociale, de pharmacoépidémiologie, de pharmacoéconomie ou de médecine factuelle. La revue publie en langue française ou anglaise des mémoires originaux, des revues générales, des lettres à la rédaction exposant des faits originaux, des correspondances à propos d'articles ou de lettres publiés dans la revue, des observations de pharmacovigilance et d'addictovigilance répondant aux normes des bonnes pratiques de publication. Elle propose également des comptes rendus et actes de congrès, et des numéros à thème en rapport avec l'actualité. Thérapies est indexé dans les principales bases de données biomédicales: Biosis Previews/Biological Abstracts, Embase/Excerpta Medica, Medline/Index Medicus, Science Citation Index.

Toxicology and Applied Pharmacology

ISSN: 0041-008X
5 Year impact factor: 4
Impact factor: 3.8

Toxicology and Applied Pharmacology publishes original scientific research of relevance to animals or humans pertaining to the action of chemicals, drugs, or chemically-defined natural products.Regular articles address mechanistic approaches to physiological, pharmacologic, biochemical, cellular, or molecular understanding of toxicologic/pathologic lesions and to methods used to describe these responses. Safety Science articles address outstanding state-of-the-art preclinical and human translational characterization of drug and chemical safety employing cutting-edge science. Highly significant Regulatory Safety Science articles will also be considered in this category. Papers concerned with alternatives to the use of experimental animals are encouraged.Short articles report on high impact studies of broad interest to readers of TAAP that would benefit from rapid publication. These articles should contain no more than a combined total of four figures and tables. Authors should include in their cover letter the justification for consideration of their manuscript as a short article.TAAP also issues a standing call for outstanding Invited Review Articles. Potential authors should contact the Editor-In-Chief and complete an Invited Review Proposal Form before preparing or submitting their Review Article. Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services . Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center

Pharmacology Biochemistry and Behavior

ISSN: 0091-3057
5 Year impact factor: 3.5
Impact factor: 3.6

Pharmacology Biochemistry & Behavior publishes original reports in the areas of pharmacology and biochemistry in which the primary emphasis and theoretical context are behavioral. Contributions may involve clinical, preclinical, or basic research. Purely biochemical or toxicology studies will not be published. Papers describing the behavioral effects of novel drugs in models of psychiatric, neurological and cognitive disorders, and central pain must include a positive control unless the paper is on a disease where such a drug is not available yet. Papers focusing on physiological processes (e.g., peripheral pain mechanisms, body temperature regulation, seizure activity) are not accepted as we would like to retain the focus of Pharmacology Biochemistry & Behavior on behavior and its interaction with the biochemistry and neurochemistry of the central nervous system. Papers describing the effects of plant materials are generally not considered, unless the active ingredients are studied, the extraction method is well described, the doses tested are known, and clear and definite experimental evidence on the mechanism of action of the active ingredients is provided. Benefits to authors We provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services. Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center.

Molecular Aspects of Medicine

ISSN: 0098-2997
5 Year impact factor: 13.6
Impact factor: 10.6

Molecular Aspects of Medicine is a review journal for Physicians and Biomedical Scientists and an official journal of the International Union of Biochemistry and Molecular Biology. Molecular Aspects of Medicine aims to encourage the bridging of the gap between clinicians of all relevant specialities and biomedical scientists. The journal anticipates that most of the authors contributing to the series will be practising clinical scientists who will develop their own personal perspective as an extended review on the molecular aspects of a field of medicine in which they are working, addressing themselves both to the doctor who is ill-at-ease with basic science, and to the basic scientist with little awareness of the problems of clinical practice. It publishes articles on a spectrum of topics in medicine to illustrate not only the molecular insights that derive from the application of basic science, but also the variety of challenging problems that medicine is able to offer the basic scientist. Submissions on from biochemistry and molecular and cell biology to physiology, pharmacology and pathology are particularly welcomed.